Unknown

Dataset Information

0

Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial.


ABSTRACT: Importance:Zoledronic acid, a third-generation aminobisphosphonate, reduces the incidence of skeletal-related events and pain in patients with bone metastases. The optimal dosing interval for zoledronic acid is uncertain. Objective:To determine whether zoledronic acid administered every 12 weeks is noninferior to zoledronic acid administered every 4 weeks. Design, Setting, Participants:Randomized, open-label clinical trial conducted at 269 academic and community sites in the United States. Patients (n?=?1822) with metastatic breast cancer, metastatic prostate cancer, or multiple myeloma who had at least 1 site of bone involvement were enrolled between May 2009 and April 2012; follow-up concluded in April 2014. Interventions:Patients were randomized to receive zoledronic acid administered intravenously every 4 weeks (n?=?911) vs every 12 weeks (n?=?911) for 2 years. Main Outcomes and Measures:The primary end point was the proportion of patients having at least 1 skeletal-related event (defined as clinical fracture, spinal cord compression, radiation to bone, or surgery involving bone) within 2 years after randomization and a between-group absolute difference of 7% as the noninferiority margin. Secondary end points included the proportion of patients with at least 1 skeletal-related event by disease type, pain as assessed by the Brief Pain Inventory (range, 0-10; higher scores indicate worse pain), Eastern Cooperative Oncology Group performance status (range, 0-4; higher scores indicate worse disability), incidence of osteonecrosis of the jaw, kidney dysfunction, skeletal morbidity rate (mean number of skeletal-related events per year), and, in a subset of 553 patients, suppression of bone turnover (assessed by C-terminal telopeptide levels). Results:Among 1822 patients who were randomized (median age, 65 years; 980 [53.8%] women; 855 with breast cancer, 689 with prostate cancer, and 278 with multiple myeloma), 795 completed the study at 2 years. A total of 260 patients (29.5%) in the zoledronic acid every 4-week dosing group and 253 patients (28.6%) in the every 12-week dosing group experienced at least 1 skeletal-related event within 2 years of randomization (risk difference of -0.3% [1-sided 95% CI, -4% to ?]; P?

SUBMITTER: Himelstein AL 

PROVIDER: S-EPMC5321662 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Importance</h4>Zoledronic acid, a third-generation aminobisphosphonate, reduces the incidence of skeletal-related events and pain in patients with bone metastases. The optimal dosing interval for zoledronic acid is uncertain.<h4>Objective</h4>To determine whether zoledronic acid administered every 12 weeks is noninferior to zoledronic acid administered every 4 weeks.<h4>Design, setting, participants</h4>Randomized, open-label clinical trial conducted at 269 academic and community sites in th  ...[more]

Similar Datasets

| S-EPMC6426213 | biostudies-literature
| S-EPMC7463577 | biostudies-literature
| S-EPMC3694249 | biostudies-other
| S-EPMC9854333 | biostudies-literature
| S-EPMC2769231 | biostudies-other
| S-EPMC5824238 | biostudies-literature
| S-EPMC8690265 | biostudies-literature
| S-EPMC6007273 | biostudies-other
| S-EPMC3717600 | biostudies-literature
| S-EPMC6702312 | biostudies-literature